October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Market volatility threatens hospitals’ liquidity as tariff-driven costs rise
- Study: CT scan radiation could drive 5% of future cancer cases
- New studies, surgical feats advance organ transplant medicine
- Commentary: Cyberattacks threaten financial survival of surgical practices
- Tariffs strain supply chains, split medical manufacturing community
- Study: Systemic gender bias embedded in surgical practice
- Literature review: Endoscope disinfection failures highlight need for stronger sterilization practices
- Study: GLP-1 drugs heighten risk of gastric residue but not perioperative pulmonary aspiration
- OAS CAHPS compliance soars to 96% among ASCs, vendor satisfaction also improves
- Knee surgical robot market set to surge, projected to reach $5.9B by 2032
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement